

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 30, 2023

R. Kirk HuntsmanChief Executive OfficerVivos Therapeutics, Inc.7921 Southpark Plaza, Suite 210Littleton, CO 80120

Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 Filed November 22, 2023 File No. 333-275726

Dear R. Kirk Huntsman:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Benjamin Richie at 202-551-7857 with any questions.

Sincerely,

Division of Corporation Finance Office of Industrial Applications and Services

cc: Lawrence A. Rosenbloom, Esq.